Compare IPSC & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPSC | IXHL |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.3M | 49.1M |
| IPO Year | 2021 | N/A |
| Metric | IPSC | IXHL |
|---|---|---|
| Price | $0.92 | $0.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 12.2M |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,337,000.00 | $12,000.00 |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | N/A |
| 52 Week Low | $0.34 | $0.08 |
| 52 Week High | $1.19 | $2.25 |
| Indicator | IPSC | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 61.52 | 52.15 |
| Support Level | $0.91 | $0.35 |
| Resistance Level | $1.05 | $0.47 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 66.72 | 48.04 |
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.